Mucosal gene transcription of ulcerative colitis in endoscopic remission

Abstract

<i>Aim/Objective</i>: Ulcerative colitis (UC) is a chronic inflammatory bowel disease. In UC, a wide range of criteria are used for disease remission, with few studies investigating the differences between disease remission and normal control groups. This paper compares known inflammatory and healing mediators in the mucosa of UC in clinical remission and normal controls, in order to better describe the remission state.<p>

<p><i>Method</i>: Mucosal biopsies from 72 study participants (48 UC and 24 normal controls) were included from the Advanced Study of Inflammatory Bowel Disease (ASIB Study), Arctic University of Norway, Norway. Clinical remission was defined as Mayo clinical score ≤ 2, with endoscopic subscores of ≤ 1. Targeted gene transcription analyses were performed using hydrolysis probes and SYBR-green.<p>

<p><i>Results</i>: Among the mucosal transcripts examined, 10 genes were regulated in remission versus normal controls, 8 upregulated pro-inflammatory transcripts (<i>IL1B</i>, <i>IL33</i>, <i>TNF</i>, <i>TRAF1</i>, <i>CLDN2</i>, <i>STAT1</i>, <i>STAT3</i> and <i>IL13Ra2</i>) and 2 downregulated (pro-inflammatory <i>TBX21</i> and anti-inflammatory <i>TGFB1</i>). In total, 14 transcripts were regulated between the investigated groups. Several master transcription factors for T-cell development were upregulated in patients with Mayo endoscopic score of 1 in comparison to 0.<p>

<p><i>Conclusions</i>: The mucosa of UC in clinical and endoscopic remission differs from normal mucosa, suggesting a remaining dysregulation of inflammatory and wound healing mechanisms.